2026年2月23日, 两名维拉治疗内幕人士出售股票, 减少了他们的股份。 On Feb. 23, 2026, two Vera Therapeutics insiders sold shares, reducing their stakes.

2026年2月23日, David Lee Johnson, Vera 治疗治疗公司COO, 出售2 579股,每股41.98美元, 股份减少了5.34%, On February 23, 2026, David Lee Johnson, Vera Therapeutics' COO, sold 2,579 shares at $41.98 each, reducing his stake by 5.34% to 45,727 shares. 另一位内幕人士Laurence Matthew Skelton以相同价格出售了1 582股股份, Laurence Matthew Skelton, another insider, sold 1,582 shares at the same price, cutting his ownership by 2.4%. 这两笔交易都向证交会申报。 Both transactions were filed with the SEC. 2月25日,该库存关闭41.68美元,低于平均数量。 On February 25, the stock closed at $41.68, below average volume. Vera治疗技术公司是剑桥生物技术公司,开发自动免疫和发炎疾病的T细胞免疫疗法,市场上限为29.2亿美元,具有协商一致的“多价购买”评级。 Vera Therapeutics, a Cambridge-based biotech, develops T-cell immunotherapies for autoimmune and inflammatory diseases, with a $2.92 billion market cap and a consensus “Moderate Buy” rating.